Hikma Pharmaceuticals PLC

    Jurisdiction
    United Kingdom
    LEI
    549300BNS685UXH4JI75
    ISIN
    GB00B0LCW083 (HIK.L)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    52 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. Read full profile

    Fundamentals

    Net revenue
    €5.10B
    Gross margin
    44.8%
    EBIT
    €902.95M
    EBIT margin
    17.7%
    Net income
    €466.73M
    Net margin
    9.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A N/A
    N/A N/A
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    £26.56
    Ex date
    Payment date
    Dividend payout ratio
    56.5%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Laura Balan Non-Executive Director +3.5K $18.21 +$63.74K
    Mazen Darwazah Executive Vice Chairman +200K $17.56 +$3.51M

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 8, 2025 (Q2 2025)

    Add to watchlist

    Notifications